KeyBanc maintains an overweight rating with GoodRX (GDRX)

Goodrx Holdings, Inc. (NASDAQ:GDRX) is one of 11 US stocks to invest in under $5. On May 14th, KeyBanc Capital Markets was published by GoodRx Holdings, Inc. (NASDAQ: GDRX) repeatedly rated “overweight” and the price target is $6.

Keybanc analyst Scott Schoenhaus is in the challenging retail pharmacy industry, GoodRx Holdings, Inc. It emphasized the current position of (NASDAQ: GDRX). Analysts said the company is making strategic moves to navigate challenges, including direct contract strategies and responses to events such as recent ritual aid bankruptcy.

A pharmacist who helps elderly customers with a GoodRX code at a local pharmacy.

Goodrx Holdings, Inc. (NASDAQ: GDRX) focuses on new opportunities to involve a wide range of players in the pharmacy ecosystem, including manufacturers, retailers, pharmacy benefits managers (PBMs), and consumers. Monthly Active Consumers (MAC) re-accession may be delayed until next year, but Goodrx Holdings, Inc. (NASDAQ:GDRX) could increase revenue per MAC through these direct contractual relationships.

Schoenhaus also shows confidence in CEO Wendy Barnes and his team’s ability to implement profitable growth plans, which could lead to a higher estimate for 2025.

Goodrx Holdings, Inc. (NASDAQ: GDRX) is an American company known for its digital healthcare platform that connects consumers, health professionals, payers, PBMS, pharmaceutical manufacturers and retail pharmacies.

Although we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater potential for a rise and pose a risk of a decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: Analysts say 11 stocks bouncing and 11 shares under $15 to buy according to a hedge fund.

Disclosure: None.